# Pliant Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pliant-therapeutics

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: http://www.pliantrx.com
- Total disclosed funding: $159M
- Latest round: Series C (Mar 11, 2020)
- Investors on record: 15

## About

Pliant Therapeutics, Inc. is a biotechnology company dedicated to developing innovative therapies for fibrotic diseases, utilizing advanced small molecule integrin inhibitors to address the root causes of fibrosis.Founded in 2015 and headquartered in San Francisco, US, Pliant Therapeutics, Inc. focuses on creating therapies for fibrotic diseases. The company has undergone significant funding events, including a Private Placement of USD 200.000 mn in July 2022, bringing its total raised capital to USD 200.000 mn. The company was founded by Bernard Coulie, who serves as its CEO. Under his leadership, Pliant has executed a total of 8 deals with its most recent deal occurring on June 2, 2020.Pliant Therapeutics is dedicated to developing therapies for fibrotic diseases, with a primary focus on two clinical-stage programs that involve the first oral, selective small molecule integrin inhibitors. These products aim to provide effective and safer treatment alternatives for various fibrotic conditions, serving healthcare providers, research institutions, and patients. The therapeutic offerings target markets with a high prevalence of fibrotic diseases, including regions in North America, Europe, and Asia.In the most recent fiscal year of 2022, Pliant Therapeutics reported revenue of USD 9.685 mn, alongside an EBITDA of USD -223.730 mn. This performance reflects the company's ongoing engagements and strategic partnerships within the healthcare sector.Pliant Therapeutics plans to advance its innovative therapies, focusing on new product launches in the coming years as clinical trials progress. The company is actively targeting expansion into new markets, particularly regions in Europe and Asia, by mid-2023. The recent funding round completed in July 2022, which raised USD 200.000 mn, will be allocated to support these initiatives, including further clinical development and market entry strategies.

## Funding rounds

- Series C, Mar 11, 2020, $52M — Schroders Capital, Menlo Ventures, Healthcare Royalty Partners, Redmile Group, Cormorant Asset Management, Farallon Capital Management, Eventide Asset Management, Novartis, S:Cubed Capital, Agent Capital, Surveyor Capital, Logos Capital
- Series B, Jul 9, 2018, $62M — Schroders Capital, Menlo Ventures, S-Cubed Capital, Cowen Investment Management, Eventide Asset Management, Agent Capital
- Series A, Feb 18, 2016, $45M — Third Rock Ventures

## Investors

- Third Rock Ventures (https://capitalatlas.ai/funds/third-rock-ventures) — Series A
- Schroders Capital (https://capitalatlas.ai/funds/schroders-capital) — Series B, Series C
- Menlo Ventures (https://capitalatlas.ai/funds/menlo-ventures) — Series B, Series C
- S-Cubed Capital — Series B
- Cowen Investment Management — Series B
- Eventide Asset Management (https://capitalatlas.ai/funds/eventide-asset-management) — Series B, Series C
- Agent Capital (https://capitalatlas.ai/funds/agent-capital) — Series B, Series C
- Healthcare Royalty Partners (https://capitalatlas.ai/funds/healthcare-royalty-partners) — Series C
- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series C
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series C
- Farallon Capital Management (https://capitalatlas.ai/funds/farallon-capital-management) — Series C
- Novartis — Series C
- S:Cubed Capital — Series C
- Surveyor Capital — Series C
- Logos Capital (https://capitalatlas.ai/funds/logos-capital) — Series C